Finger-prick blood samples taken at home could help to provide a simple and convenient way to predict acute hereditary angioedema (HAE) attacks, preliminary results from the Hereditary Angioedema Kininogen Assay (HAEKA) study in Germany suggest. Samples collected during attacks over the study’s course are expected to lead to the discovery…
News
Takhzyro (lanadelumab), an approved under-the-skin injection therapy to prevent swelling attacks in people with hereditary angioedema (HAE), will soon be available at a lower cost to patients in Poland and, likely, those in Australia. Poland’s Minister of Health approved access to and reimbursement for Takhzyro for about 50…
A retrospective study by the National Institutes of Health (NIH) suggests that healthcare costs for those with rare diseases have been underestimated, possibly being three to five times higher than for those without rare diseases. This study provides evidence of the potential effect rare diseases may have on public health…
In their continued efforts to improve health equity for people with rare diseases, Global Genes and RARE-X have joined forces to help advocacy groups collect patient data and make the most of that information. “Patient data is perhaps the most valuable asset rare disease communities can leverage to…
Patients with hereditary angioedema (HAE) are willing to try new therapies that can effectively lessen disease burden with less frequent dosing, according to an interview-based study conducted by Astria Therapeutics. The findings were shared in a poster, titled “Burdens of Disease and Treatment in Hereditary…
Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…
HAE International (HAEi) has expanded its free online training platform to include new courses on advocacy, disease-related information, and resources. “The HAEi Advocacy Academy is the premier online learning platform for the HAE Community,” Fiona Wardman, the non-profit’s chief regional patient advocate, said in a press release.
Adalvo has completed a mandatory requirement for a marketing authorization in the European Union for its generic version of Firazyr (icatibant injection), which is approved for acute attacks in adults with hereditary angioedema (HAE), the company has announced. The successful closure of the decentralized procedure came more…
The Rare Disease Diversity Coalition (RDDC) awarded $600,000 in grants to ease the disparities faced by rare disease patients of color. These Impact Rare Disease Solution grants will go five RDDC steering committee working groups, which aim to identify problems for rare disease communities and advocate for solutions. The five…
Use of Takhzyro (lanadelumab) for at least six months led to fewer hereditary angioedema (HAE) attacks and treated attacks, a case review study from Canada reported. Three of its 12 patients went into complete remission, and all enjoyed a more comfortable social life, the investigators noted. The study, by…
Recent Posts
- Biocryst expands HAE treatment portfolio with Astria acquisition
- When executing a plan, each person must do the right job at the right time
- Blood pressure drug lisinopril causes gut swelling in man, 54, in rare case
- Rare Disease Week is an opportunity to show that rare is not invisible
- Case highlights rare, life-threatening reaction to common antibiotic